SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).

圣地亚哥，2023年10月25日（GLOBE NEWSWIRE）-Oncenternal Therapeutics，Inc。（纳斯达克股票代码：ONCT），一家专注于开发新型肿瘤疗法的临床阶段生物制药公司，今天宣布增加Matthew Smith，医学博士，博士至其前列腺癌科学咨询委员会（SAB）。

Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal’s next steps in the clinical development of its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534, which is currently under investigation in an ongoing Phase 1/2 clinical study, ONCT-534-101. “We wholeheartedly welcome Dr.

Smith博士以及其他前列腺癌SAB成员将帮助指导其新型双作用雄激素受体抑制剂（DAARI）ONCT-534临床开发的下一步，ONCT-534目前正在进行中的研究阶段1/2临床研究，ONCT-534-101。“我们坚决欢迎博士。

Smith to Oncternal’s Prostate Cancer Scientific Advisory Board,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “We believe Dr. Smith’s expertise and his experience leading global registrational studies for novel prostate cancer therapeutics will be instrumental in helping us shape the clinical and registrational strategy for ONCT-534.” “There is a significant unmet need for patients with metastatic prostate cancer and disease progression despite treatment with currently available AR pathway inhibitors, such as abiraterone acetate and enzalutamide,” said Matthew Smith, M.D., Ph.D.

Smith to Oncernal的前列腺癌科学顾问委员会，“Oncernal的总裁兼首席执行官James Breitmeyer博士，博士说。“我们相信博士。史密斯的专业知识和他在新型前列腺癌治疗药物全球注册研究方面的经验将有助于我们制定ONCT-534的临床和注册策略。”Matthew Smith博士说：“尽管用目前可用的AR途径抑制剂如醋酸阿比特龙和恩扎鲁胺治疗，转移性前列腺癌和疾病进展的患者仍然存在显着的未满足需求。”。

“I look forward to working with the Oncternal team to help bring their dual-acting AR inhibitor to patients. Preclinical studies suggest that ONCT-534 may address the most common escape mechanisms of metastatic castration-resistant prostate cancer, including activating mutations in the AR ligand-binding domain and constitutively active splice variants such as AR-V7.” Dr.

“我期待与国际团队合作帮助将他们的双作用AR抑制剂带到患者身上，临床前研究表明ONCT-534可能解决转移性去势抵抗性前列腺癌最常见的逃避机制，包括激活AR配体结合结构域和组成型活性剪接变体如AR-V7。

Matthew R. Smith is Director of the Genitourinary Oncology Program at Massachusetts General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School. He is an internati.

Matthew R.Smith是马萨诸塞州总医院癌症中心泌尿生殖肿瘤项目主任，哈佛医学院医学教授。他是一名实习生。